Safety experience with caspofungin in pediatric patients

Related Experiment Video

Updated: Jun 20, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

Theoklis Zaoutis1, Thomas Lehrnbecher, Andreas H Groll

  • 1Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. zaoutis@email.chop.edu

The Pediatric Infectious Disease Journal
|September 26, 2009
PubMed

Insights

Caspofungin demonstrated a favorable safety profile in pediatric patients across multiple clinical trials. The antifungal medication was well-tolerated, with most adverse events being mild and rarely requiring discontinuation.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Infectious Diseases

Background:

  • Caspofungin is an echinocandin antifungal agent used to treat serious fungal infections.
  • Pediatric populations often have unique pharmacokinetic and safety considerations for antifungal therapies.
  • Understanding the safety of caspofungin in children is crucial for its appropriate clinical use.

Purpose of the Study:

  • To evaluate the safety and tolerability of caspofungin in a large pediatric patient cohort.
  • To identify common adverse events associated with caspofungin treatment in children.
  • To assess the severity and management of adverse events in this population.

Main Methods:

  • Analysis of safety data from 5 pivotal clinical registration studies.
  • Inclusion of 171 pediatric patients aged 1 week to 17 years.
  • Review of adverse events, including drug-related events, severity, and treatment discontinuation.

Main Results:

  • Caspofungin was administered for a mean duration of 12.1 days.
  • The most frequent drug-related adverse events included fever, elevated AST, elevated ALT, and rash.
  • Serious adverse events and treatment discontinuations due to adverse events were infrequent.

Conclusions:

  • Caspofungin exhibits good tolerability in pediatric patients across a wide age range.
  • The identified adverse events are generally manageable and do not typically necessitate treatment cessation.
  • Caspofungin represents a safe and effective treatment option for fungal infections in children.

More Related Videos

Generation of Fluorescent Protein Fusions in Candida Species09:27

Generation of Fluorescent Protein Fusions in Candida Species

Published on: March 4, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).